A prospective randomised comparative study of metformin versus myoinositol plus d-chiroinositol combination therapy in polycystic ovarian syndrome

Polycystic ovarian syndrome is one of the most common endocrine disorders in women of reproductive age. The Rotterdam Criteria is to be fulfilled to diagnose the syndrome which requires the presence of two out of three conditions: Oligomenorrhea and/or anovulation, clinical and/or biochemical signs of hyperandrogenism that may be associated with hirsutism, and ultrasound findings showing polycystic ovaries. Hyperandrogenism is the cornerstone of the syndrome. Insulin resistance and resultant hyperinsulinaemia contribute to hyperandrogenism in these patients. Weight loss or pharmacologic interventions that lower insulin levels have shown to significantly reduce androgen levels and improve menstrual cycle patterns in many of these women. This study is planned specifically to evaluate the efficacy of metformin versus myoinositol plus d-chiroinositol combination therapy in PCOS patients and its subsequent effects on their clinical, hormonal and radiodiagnostic dimensions. The present study will be prospective, randomized parallel design interventional study for the duration of nine months. 50 newly diagnosed PCOS patients from the department of Obstetrics & Gynaecology, Government Medical College, Amritsar will be randomly divided into 2 groups, one group will be given Metformin 500 mg BD & other group Myoinositol plus d-chiroinositol combination therapy 1000 mg BD daily for 9 months. Follow up will be done at 3,6,9 months. At each visit, LH, FSH, AMH, testosterone, insulin, progesterone, estrogen and ultrasonic evidences will be evaluated.